Company intelligence / Profile preview

Seroba Life Sciences

Dublin, Ireland

Ownership: Private
Development stage: Other

Overview

Seroba Life Sciences is a European life sciences venture capital firm that invests in biotech and medtech companies. The firm has made 50 investments and achieved 9 portfolio exits. Notable exits include Fusion Pharmaceuticals acquired by AstraZeneca for up to $2.4 billion in 2024 and Endotronix acquired in July 2024. Recent investments include Azafaros ($146.7M Series B in May 2025), Perfuze ($23.93M Series B in March 2025), and participation in Deciphex's €31M Series C in January 2025.

Industry: Investors

Beyond the preview

Go deeper on Seroba Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seroba Life Sciences.

Explore the full profile